Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

Eli Lilly's acquisition of Verve Therapeutics, a gene therapy company focused on cardiovascular disease, has spurred gains in other gene-editing stocks, signaling renewed M&A interest in the sector. Following the announcement, Crispr Therapeutics (CRSP) shares rose 3.9% and Intellia Therapeutics (NTLA) climbed 6.9%, while Beam Therapeutics (BEAM) also saw gains, reflecting investor optimism about the potential of gene-editing therapies; this acquisition is part of a broader trend of increased M&A activity in the pharma/biotech space during 2025, with companies like Sanofi, Johnson & Johnson and Novartis also making acquisitions to expand their portfolios.

Analysis

Eli Lilly's (LLY) recent agreement to acquire Verve Therapeutics (VERV) for its in vivo gene therapies for heart disease, including VERVE-102, has catalyzed positive sentiment across the gene-editing sector. This is evidenced by share price increases for Crispr Therapeutics (CRSP) and Intellia Therapeutics (NTLA), which rose 3.9% and 6.9% respectively on June 17, and gains for Beam Therapeutics (BEAM). Conversely, Editas Medicine (EDIT) pared its initial gains, finishing in negative territory, indicating a selective investor response. The LLY-VERV deal underscores a broader resurgence in mergers and acquisitions within the pharma/biotech industry in 2025, following a more subdued 2024, with a notable focus on portfolio expansion through innovative pipelines in areas like gene editing, rare diseases, and obesity. Key players in the gene-editing space continue to advance their platforms: NTLA is progressing with nex-z for ATTR amyloidosis and NTLA-2002 for hereditary angioedema; CRSP, in collaboration with Vertex Pharmaceuticals (VRTX), achieved the first approval for a CRISPR/Cas9 therapy, Casgevy, in November 2023; and BEAM is developing BEAM-101 for sickle cell disease, which recently received FDA orphan drug designation. This M&A trend is further exemplified by Sanofi's (SNY) planned $9.5 billion acquisition of Blueprint Medicines (BPMC), Johnson & Johnson's (JNJ) $14.6 billion purchase of Intra-Cellular Therapies (ITCI), and Novartis's (NVS) impending acquisition of Regulus Therapeutics (RGLS). The acceleration of M&A is anticipated to continue in 2025, driven by substantial cash reserves held by major pharmaceutical companies and investor pressure for business diversification.

Key Decisions for Investors

• Investors should consider the heightened M&A activity in the gene-editing sector, exemplified by the LLY-VERV deal, as a potential catalyst for companies with promising pipelines like CRSP, NTLA, and BEAM.
• It is crucial to monitor clinical development milestones and regulatory approvals for individual gene-editing companies, as these events are primary drivers of valuation and can lead to significant stock price movements.
• The divergent performance of Editas Medicine suggests that despite sector-wide optimism, company-specific risks remain; therefore, thorough due diligence on individual assets and technology platforms is essential before committing capital.
• Given the expectation of continued M&A in pharma/biotech through 2025, investors should assess how potential consolidation could impact their holdings and identify other potential acquisition targets.